Adma Biologics Stock Price, News & Analysis

ADMA Biologics, Inc. (NASDAQ: ADMA) has received FDA approval for its ADMA BioCenters plasma collection facility in Knoxville, Tennessee, which began operations in Q3 2020. This approval enhances the company's raw material supply chain and manufacturing control. ADMA aims to open up to ten plasma collection centers by 2024. The facility uses state-of-the-art equipment and employs 50 trained healthcare workers. This milestone is expected to improve product yields and margins, positioning ADMA for future growth and profitability.

ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CMS has issued a permanent J-code (J1554) for ASCENIV™, effective April 1, 2021, enhancing reimbursement processes. This J-code is expected to facilitate patient access and simplify claims processing in outpatient settings. CEO Adam Grossman highlighted that this milestone supports the company's goal of achieving over $250 million in revenue by 2024. ASCENIV is a plasma-derived immune globulin approved for treating primary immunodeficiency in patients aged 12 and older.

ADMA Biologics reported preliminary unaudited revenues of $13.9 million for Q4 2020, marking a 16% increase from Q4 2019, and full-year revenues of $42.2 million, a 44% increase compared to 2019. The company anticipates significant value-creating FDA decisions in 2021 that could enhance supply chains and improve margins. ADMA plans to continue revenue growth and aims for revenues exceeding $250 million by 2024, supported by new plasma collection centers and expanded production capabilities.

ADMA Biologics announced that the Centers for Medicare and Medicaid Services (CMS) has approved a new reimbursement C-code, C9072, and transitional pass-through payment status for ASCENIV, effective January 1, 2021. This approval facilitates streamlined reimbursement for ASCENIV in outpatient settings, allowing infusion at list price plus 6%. CEO Adam Grossman stated this is a significant milestone, enhancing insurance coverage and patient access. ADMA aims to achieve over $250 million in revenue from its products by 2024.

ADMA Biologics announced the approval of a stockholder rights plan by its Board of Directors on December 16, 2020, aimed at safeguarding stockholders from potential hostile takeovers. This plan allows for a dividend distribution of one right for each share of common stock, with a record date of December 30, 2020, and an expiration on December 15, 2021. The rights plan is triggered if ownership exceeds 10% without Board approval, enabling rights holders to purchase shares at a market value of twice the exercise price. Further details will be provided in SEC filings.

ADMA Biologics announced an amendment to its senior secured term loan with Perceptive Advisors, increasing the credit facility to $100 million. The amendment includes a two-year extension of the interest-only period, maturing in March 2024, at an unchanged borrowing rate of 11%. The $15 million tranche was used to settle obligations under a subordinated note with Biotest AG. ADMA aims to achieve $250 million in topline revenues by 2024 and aims for profitability before the loan's new maturity date.

ADMA Biologics has announced the opening of a new plasma collection facility in Maryville, Tennessee, which is part of its strategy to enhance plasma supply chain control. The facility is designed to support increased plasma collection throughput as the company aims to establish a self-sufficient supply chain. ADMA has submitted a Biologics License Application (BLA) for this center to the FDA, expecting a decision by Q4 2021. The facility will be equipped with advanced technology to improve donor experience and will employ 50 trained staff members.

ADMA Biologics (Nasdaq: ADMA) announced that its President and CEO, Adam Grossman, will participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on November 17, 2020, at 7:55 a.m. ET. The event will be accessible via a webcast on the company's website, archived for 90 days post-event.

ADMA is focused on developing specialty plasma-derived biologics for immune-compromised patients and markets three FDA-approved products: BIVIGAM®, ASCENIV™, and NABI-HB®. The company operates a plasma fractionation facility in Boca Raton, Florida.

ADMA Biologics reported total revenues of $28.3 million for the first nine months of 2020, a 63% increase year-over-year. The third quarter generated $10.3 million, marking a 42% growth compared to Q3 2019. Despite revenue growth, net loss for the quarter was $16.9 million, attributed to rising costs and increased operational expenses. The company is ahead of schedule in expanding its plasma collection centers, aiming for five to ten new centers by 2025. ADMA's cash reserves rose to $59.7 million as of September 30, 2020.